NICE Reverses Stance On BMS' HCV Pill Daklinza
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has reversed its previous position to limit use of Bristol-Myers Squibb Company's HCV pill Daklinza to only patients with genotypes 1 and 4 without cirrhosis. It now says in final draft guidance issued Oct. 16 that presentations made by the US drug maker since that preliminary draft opinion was issued in July has convinced the HTA to include genotype 3 patients in Daklinza's label.
You may also be interested in...
Daklinza has been part of the standard of care in genotype 3 HCV, but the launch of Gilead's Epclusa and an EU ramp-up of Merck's Zepatier are expected to erode that over time.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.